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Abstract
Since the discovery of CCR5 as a coreceptor for HIV entry, there has been interest in blockade of the receptor for
treatment and prevention of HIV infection. Although several CCR5 antagonists have been evaluated in clinical trials,
only maraviroc has been approved for clinical use in the treatment of HIV-infected patients. The efficacy, safety and
resistance profile of CCR5 antagonists with a focus on maraviroc are reviewed here along with their usage in
special and emerging clinical situations. Despite being approved for use since 2007, the optimal use of maraviroc
has yet to be well-defined in HIV and potentially in other diseases. Maraviroc and other CCR5 antagonists have the
potential for use in a variety of other clinical situations such as the prevention of HIV transmission, intensification of
HIV treatment and prevention of rejection in organ transplantation. The use of CCR5 antagonists may be poten-
tiated by other agents such as rapamycin which downregulate CCR5 receptors thus decreasing CCR5 density.
There may even be a role for their use in combination with other entry inhibitors. However, clinical use of CCR5
antagonists may have negative consequences in diseases such as West Nile and Tick-borne encephalitis virus infec-
tions. In summary, CCR5 antagonists have great therapeutic potential in the treatment and prevention of HIV as
well as future use in novel situations such as organ transplantation. Their optimal use either alone or in combina-
tion with other agents will be defined by further investigation.
Introduction
After the discovery that HIV gains entry to cells by
binding the CD4 receptor [1], research initially focused
on development of inhibitors that could block this bind-
ing step. However, this line of inquiry led to the realiza-
tion that CD4 receptor binding was necessary but not
sufficient for HIV to enter the host cell; a second step –
a coreceptor – was also required. The coreceptors
CCR5 (CC chemokine receptor 5) [2-5] and CXCR4
(CXC chemokine receptor 4) [6-9] were discovered a
few years later. Identification of the three natural ligands
of CCR5 – (Regulated upon Activation, Normal T-cell
Expressed, and Secreted [RANTES], macrophage inflam-
matory protein-1 alpha [MIP-1a], and macrophage
inflammatory protein-1 beta [MIP-1b]) – as potent inhi-
bitors of HIV [10] quickly led to research to find syn-
thetic compounds to block the receptor and thus
prohibit viral entry.
CCR5 is expressed on a number of cells including
activated T lymphocytes, macrophages, and dendritic
cells [11], and CCR5-tropic HIV-1 strains are
predominantly involved in transmission of the virus
[12]. Mutation in the CCR5 gene leading to a 32-base
pair deletion (Δ32) in the CCR5 protein and an absence
of CCR5 on the surface of cells causes homozygotes for
Δ32 to be almost completely resistant to HIV-1 infec-
tion [13-15]. Additionally, heterozygotes for Δ32 have
delayed HIV disease progression, slower declines in CD4
cell counts, and lower average circulating viral loads
[16]. Taken together, this information provided an
enticing target for pharmaceutical intervention against
HIV-1 infection.
Several products targeted against CCR5 have been
developed (Table 1), though only one is currently
approved by the U.S. Food and Drug Administration
(FDA) for treatment of HIV-1 infection. The pharma-
ceutical agents active against CCR5 represent a comple-
tely new class of antiretroviral drugs, ones that are not
antiretrovirals in the strict sense that they are not direc-
ted against HIV’s various enzymes, but instead block a
host cell receptor to diminish HIV’s access to the host’s
cells. Five different CCR5 antagonists – maraviroc, vicri-
viroc, aplaviroc, INCB009471 and TBR 652 – have been
developed and brought to human trials (Table 1).
Aplaviroc advancement was halted after results of two
Phase IIb trials showed higher than expected rates of
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any medium, provided the original work is properly cited.idiosyncratic hepatotoxicity [17]. Vicriviroc is currently
in advanced clinical development (Phase III) but has yet
to be FDA-approved. Maraviroc was initially approved
by the FDA in August 2007 for the treatment of HIV-
infected patients experiencing virologic failure due to
resistance to other classes of antiretroviral drugs and,
subsequently, for the treatment of antiretroviral naïve
patients. INCB009471 is an oral CCR5 antagonist with
an extended half-life such that it can be given once
daily; results from a Phase I and II trials were presented
in 2007 [18-20], but the company has decided not to
continue further trials. TBR 652 is the fifth new CCR5
antagonist, and Phase I trial results were presented at a
conference in early 2010 [21,22]. The novelty of this
class of therapeutics is that this is the first class of anti-
HIV drugs that focus exclusively on host cellular path-
ways and not on direct inhibition of viral enzyme
mechanisms.
Two other products in development are antibodies to
the CCR5 receptor: PRO 140 and HGS004. PRO 140 is
a humanized monoclonal antibody that binds to CCR5
and inhibits CCR5-tropic HIV-1 in vitro,a n di tw a s
recently shown to have potent antiviral activity after a
single dose in a Phase Ib monotherapy, dose escalation
trial [23]. HGS004 is a human immunoglobulin G4
monoclonal antibody against CCR5 that was also
recently tested in a Phase Ib trial [24] that established
its safety and in vivo activity against HIV-1.
Mechanism of action
The process by which HIV infects a host cell is compli-
cated and requires multiple steps. First, the env protein
(gp120) on the surface of the virus binds to cellular
CD4 receptors. The binding of gp120 leads to a confor-
mational change that exposes the V3 loop; the exposed
V3 loop of gp120 then interacts with and binds to a cor-
eceptor on the host cell (either CCR5 or CXCR4) [25].
After the coreceptor is bound, another conformational
change in the viral envelope unmasks gp41, which can
then insert into the cell’s membrane [26]. This step
brings the virus into close proximity with the cell, lead-
ing to fusion of the virus with the cell [26]. CCR5
antagonists bind to the CCR5 receptor and induce a
conformational change to it such that the V3 loop of
the viral gp120 is unable to recognize and bind [27-30].
CCR5 antagonists act as allosteric, non-competitive
inhibitors of the receptor [25]. CCR5 antibodies work by
binding to the extracellular domain of the CCR5
receptor and thereby inhibit interaction between gp120
and the coreceptor [31,32]. The result of binding of
either an antagonist or an antibody is blockade of the
binding interaction which prevents HIV from entering
the host cell.
Tropism
As noted above, the structural change that occurs after
CD4 binding leads to exposure of the V3 loop of gp120,
and this V3 loop is the area of the envelope that inter-
acts with the coreceptor. The amino acid sequence of
the V3 variable domain appears to be the primary deter-
minant of which coreceptor is utilized, i.e. the tropism
of the virus [33]. Tropism refers specifically to which
coreceptor the virus is designed to utilize to gain entry
to host cells. There are 4 categories of HIV-1 tropism:
1) R5 – v i r u s e st h a tb i n do n l yt ot h eC C R 5c o r e c e p t o r ;
2) X4 – viruses that bind only to the CXCR4 coreceptor;
3) dual tropism – viruses that can bind to either core-
ceptor; and 4) mixed tropism – mixed populations that
include both R5- and X4-tropic viruses [34,35].
An important relationship between tropism/coreceptor
usage and different phenotypic characteristics of the
virus has been clearly established. Originally, in vitro
studies demonstrated that viruses that were syncytium-
inducing on T-cell lines and preferentially replicated on
T lymphocytes were more pathogenic [36]; these fea-
tures were also correlated with more rapid progression
t oA I D Sa n dA I D S - r e l a t e dm o r t a l i t y[ 3 7 , 3 8 ]a n dw e r e
eventually identified as X4-tropic viruses. Non-syncy-
tium-inducing viruses were noted to replicate best in
monocyte-macrophages, have a less virulent clinical
course, and correspond to R5-tropic viruses [36-40].
The dynamic nature of HIV tropism has important
ramifications for viral transmission and pathogenicity.
R5-tropic viruses predominate in transmission events
and infection of new patients as they appear to be more
efficiently transmitted than X4-tropic strains [41];
Table 1 CCR5 Antagonists in Clinical Trials
Product Mechanism of Action Company Status
Maraviroc Non-competitive inhibitor Pfizer FDA Approved
Vicriviroc Non-competitive inhibitor Schering-Plough Phase III completed
Aplaviroc Non-competitive inhibitor GlaxoSmithKline Development discontinued
INCB009471 Non-competitive inhibitor Incyte Phase I/IIa completed
TBR 652 Non-competitive inhibitor Tobira Phase II completed
Pro 140 Antibody Progenics Phase II
HGS004 Antibody Human Genome Sciences Phase I completed
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ing strain in most patients with early HIV infection [42].
Further evidence, albeit indirect, for the predominance
of R5-tropic virus in transmission events comes from
the relative resistance to infection of homozygotes for
Δ32 within the CCR5 gene [13-15]. One factor that is
likely to play a role in the preferential transmission of
R5-tropic strains is the high levels of expression of
CCR5 on cells in the genital mucosa [43], thus allowing
R5-tropic strains an easier pathway into the host.
X4-tropic viruses are found much less often in the
early stages of HIV infection and are thought to be
uncommonly involved with transmission events. How-
ever, there is a strong correlation between disease pro-
gression to AIDS and coreceptor switching from CCR5
to CXCR4 [40]. It is not entirely clear if this association
i sc a u s a l ,i . e .w h e t h e rC X C R 4 receptor usage is patho-
genic in leading to clinical progression to AIDS, or if it
is simply a consequence of disease progression [44]. Sev-
eral studies have shown a significantly increased risk of
disease progression among patients with X4-tropic or
dual/mixed virus [42,45,46]. One of the main (yet still
theoretical) concerns about the clinical use of CCR5
antagonists is that they might promote the emergence
of X4-tropic viruses that could then go on to accelerate
disease progression to AIDS [44]. At this point in time,
however, accumulating clinical trial data has not sub-
stantiated this fear.
The majority of reports on tropism have come from
cohorts of patients infected with HIV-1 subtype B (from
the U.S. and western Europe), but new research is emer-
ging to suggest that tropism is also affected by HIV-1
subtype or clade [47]. X4- and mixed tropic viruses
appear to be much less common in subtype C-infected
patients, and this relationship appears to hold regardless
of CD4 cell count or disease stage [48-50]. In subtype
C-infected patients, X4-tropic strains have been found
after prolonged treatment with ART. Differences in
tropism between subtypes B and C could be related to
intrinsic differences in the conformation of the V3 loop
that could affect the evolution of HIV from R5- to X4-
tropic [51]. The prevalence of X4-tropic virus also
appears to be lower in subtype A [52], but another
study found X4-tropic viruses emerging in patients with
progression to AIDS [53]. Two small studies with sub-
type D viruses have found a higher proportion of X4-
and mixed-tropic viruses [54,55], whereas two small stu-
dies of subtype E viruses (more prevalent in southeast
Asia) found a similar proportion of R5-, X4-, and mixed
tropic viruses as that usually found with subtype B
[56,57]. Overall, the different subtypes appear to have
considerable variability in coreceptor usage, and these
differences may have a significant impact on the ability
to use CCR5 antagonists in different countries.
From a clinical standpoint, it is imperative to assess
viral tropism prior to prescribing a CCR5 antagonist
since the drugs are only effective against R5-tropic
viruses. Tropism can be evaluated by genotypic or phe-
notypic assays. Genotypic assays evaluate the amino acid
sequence of the V3 region of gp120, the primary deter-
minant of tropism [58]. Genotypic algorithms to predict
viral tropism based on V3 genetic sequences are in
development [59], though the results have not always
correlated well with phenotypic assays [58]. At this time,
genotypic assays have not yet entered into clinical
practice.
Phenotypic assays are the most widely used to date in
clinical practice; the original test was the Trofile™ assay
by Monogram Biosciences [60]. This test identified
X4-tropic strains with a sensitivity of 10%, but it could
not differentiate between dual-tropic viruses and mixed
populations of X4- and R5-tropic strains [58,61]. The
Trofile™ test had the disadvantages of being expensive
and both time- and labor-intensive. Additionally, the
fact that not all minority variants are detected with this
assay is suboptimal because these strains can lead to
treatment failure if undetected.
Failure of the Trofile™ assay to detect minority
variants led to the development of an enhanced sensitiv-
ity tropism assay. This assay is able to detect X4 virus
with a sensitivity of 100% when at least 0.3% of the viral
population is X4-tropic [25]. Using this enhanced assay
on previously collected samples from major CCR5
antagonist trials found that a large number of virological
failures were explained by pre-existing X4-tropic virus
that was not detected using the original Trofile™ assay
[62,63]. These results reinforce the importance of these
assays, though further advances will be necessary before
they become standard in routine clinical practice.
Pharmacology
Maraviroc is administered orally at a usual dose of 300
mg twice daily and can be given without regard to fast-
ing or fed state. It is rapidly absorbed and has peak
drug concentrations between 30 minutes and 4 hours
after dosing [64]. At the usual dose of 300 mg, bioa-
vailability is 33% [65], and steady state is reached
within 7 days [64]. The drug is widely distributed in
the body [65]; preclinical studies with rats found poor
penetration into the central nervous system [66], but
several small studies in humans demonstrated that
maraviroc enters the cerebrospinal fluid at therapeutic
levels [67-69]. Tiraboschi et al [67] also found
maraviroc levels several times the IC50 in semen.
Another study examined the concentration of mara-
viroc in cervicovaginal fluid and found that drug levels
were significantly higher than in plasma at the same
time and even 72 hours after oral dosing [70]. This
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tion of transmission [see Potential uses below].
Maraviroc is a substrate for the hepatic cytochrome
P450 enzyme, CYP3A4 (though it does not inhibit or
induce the enzyme itself), as well as P-glycoprotein [65],
and so dosing adjustments are required when it is given
in combination with other inducers and inhibitors of
these enzymes. For inhibitors of CYP3A4 like protease
inhibitors, itraconazole, or clarithromycin, the dose of
maraviroc is reduced to 150 mg twice daily [65,71].
With inducers of CYP3A4 (e.g. efavirenz or rifampin),
maraviroc dosing should be increased to 600 mg twice
daily [65,72]. Dosing does not need to be adjusted when
used in combination with other antiretrovirals like teno-
fovir, nevirapine, enfuvirtide, or raltegravir. Maraviroc
concentrations were mildly increased in HIV negative
patients with mild and moderate hepatic impairment,
though no change in dosing was recommended [65,73].
The majority of the drug is excreted unchanged in feces
(~75%) while about 20% is excreted in urine [64]. No
dosage adjustment is necessary in patients with renal
insufficiency. Lastly, maraviroc pharmacokinetics were
not found to be altered in men vs. women or in patients
of various races/ethnicities [65].
Clinical experience with CCR5 antagonists
To date there has only been one CCR5 antagonist, mar-
aviroc, approved for the treatment of HIV by the U.S.
FDA. This review will therefore focus on maraviroc
except where other agents in development have unique
characteristics or findings that are important to under-
stand when considering the CCR5 antagonist class.
Efficacy
The clinical experience with maraviroc (MVC) in HIV
infected patients essentially began with two small
phase IIa dose escalation studies evaluating the anti-
viral efficacy of MVC monotherapy over a period of 10
days [74]. These studies evaluated MVC at multiple
doses in fed and fasted states compared to placebo in
82 patients. Study participants had to have CCR5 tro-
pic virus, and the mean baseline CD4 cell count and
viral load was 544 cells/mm
3 and 4.62 log10 HIV-1
RNA copies/ml, respectively. Of the 63 patients who
completed 10 days of therapy, all who received MVC
at least 100 mg once or twice daily achieved a mean
reduction of viral load at Day 11 of 1.13-1.60 log10
HIV-1 RNA copies/ml. The lower dose groups
achieved reductions of 0.43 and 0.66 log10 HIV-1 RNA
copies/ml. Interestingly, the maximal viral load decline
occurred in several patients after discontinuation of
the drug. The median time to viral load nadir was
10-15 days in the different dose groups and viral
r e b o u n dd i dn o to c c u ri m m e d i a t e l y .
Treatment experienced patients
Following the viral load reductions seen in the Phase II
studies, maraviroc was evaluated in R5-tropic, treat-
ment-experienced HIV-infected patients [75]. Patients
were randomized to receive once or twice daily MVC in
combination with an optimized background regimen
(OBR) vs. an OBR (the placebo arm) alone in the
MOTIVATE (Maraviroc versus Optimized Therapy in
Viremic Antiretroviral Treatment-Experienced Patients)
trials. These trials were conducted in Canada and the
U.S. (MOTIVATE 1) and Australia, Europe and the U.S.
(MOTIVATE 2). The results of the trials were pooled
for analysis with a total of 1,049 patients (414 MVC
once daily; 426 MVC twice daily; 201 placebo (OBR)). It
is notable that 955 other patients who were screened for
these two studies were excluded due to dual, mixed or
CXCR4 tropism. The primary study endpoint, the mean
change from baseline in the log10 HIV RNA levels at 48
weeks, was -1.68 for MVC once daily, -1.84 for MVC
twice daily and -0.79 for the placebo arm. More impor-
tantly, the percentage of patients achieving a viral load
of < 50 copies/ml at 48 weeks was 43% for MVC once
daily, 46% for MVC twice daily and 17% for the placebo
arm, which were statistically significant between each
MVC arm and placebo arm (p < 0.001). There were also
statistically significant greater mean CD4 cell count
increases from baseline in the MVC arms (116 cells/
mm
3 in MVC once daily, 124 cells/mm
3 MVC twice
daily, 61 cells/mm
3 in placebo) [76]. Subanalyses of the
pooled MOTIVATE results revealed a treatment benefit
of MVC in combination with OBR when compared to
placebo in combination with OBR at screening viral
load < or > 100,000 copies/ml, baseline CD4 cell count
at all strata (< 50, 50-100, 101-200, 201-350, and > 350
cells/mm
3), baseline R5 tropism, viral subtype (B vs.
non-B), enfuvirtide use, Δ32 genotype, race, gender, gen-
otypic susceptibility score (GSS), phenotypic susceptibil-
ity score, overall susceptibility score, and first use of
enfuvirtide, lopinavir-ritonavir or tipranavir-ritonavir
[77]. Importantly, these analyses revealed a significant
benefit of using an additional active new antiretroviral
agent in combination with maraviroc. The results of
these studies led to FDA approval of maraviroc for
treatment experienced patients.
Those patients who failed screening for the MOTI-
VATE trials due to dual or mixed tropic virus were
offered the opportunity to enroll in a trial evaluating
maraviroc in treatment experienced patients with dual,
mixed or CXCR4 tropism. In this study 186 patients
were randomized to once or twice daily MVC or pla-
cebo in combination with an OBR [78], and there were
167 evaluable patients. The primary endpoint, the mean
change in viral load from baseline at 24 weeks, was 0.91,
1.20 and 0.97 log10 copies/ml HIV RNA in the once
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tively. Similarly, the proportion of patients with HIV
RNA < 50 copies/ml was 21%, and 27%, and 16% (once
daily MVC, twice daily MVC, placebo). Neither nonin-
feriority or superiority of the MVC arms in comparison
with the placebo arm was established. Mean CD4 cell
count increases from baseline were 60 cells/mm
3 in the
once daily MVC arm, 62 cells/mm
3 in the twice daily
MVC arm , and 36 cells/mm
3 in the placebo arm at 24
weeks. These differences were statistically significant at
24 weeks, but they were no longer statistically significant
at 48 weeks. Overall, there was little virologic or immu-
nologic benefit of maraviroc for the treatment of dual or
mixed tropic virus.
Maraviroc has also been evaluated in combination
with raltegravir and etravirine in a review of 28 treat-
ment experienced patients with R5 tropic virus who
were started on this combination through expanded
access programs. At 48 weeks, all patients had an HIV
RNA < 400 copies/ml and 26/28 (93%) had an HIV
RNA < 50 copies/ml [79]. There is one case report of a
treatment experienced patient with resistant HIV-2
infection that was successfully treated with raltegravir
and maraviroc based therapy [80].
Treatment naïve patients
The success of maraviroc in the treatment experienced
trials and the fact that a CCR5 antagonist would have
the greatest potential for effectiveness in populations
with predominantly CCR5 tropic virus led to an
evaluation of MVC in antiretroviral treatment naïve
HIV-infected patients. The MERIT (Maraviroc versus
Efavirenz in Treatment-Naive Patients) trial was a phase
IIb/III, double-blind, placebo-controlled trial that evalu-
ated the safety and efficacy of MVC vs. efavirenz in
patients with R5 tropic virus from Australia, Europe,
North America, South America and South Africa [63].
Similar to the MOTIVATE trials, patients were initially
randomized to receive MVC 300 mg once or twice daily
or efavirenz 600 mg once daily in combination with co-
formulated zidovudine and lamivudine. In contrast to
the MOTIVATE trials, only 17% of the patients
screened for the MERIT study were excluded for having
X4 tropic virus. In total, 895 patients were randomized,
but an interim analysis found that patients receiving
once daily MVC fell outside of the prespecified thresh-
olds for non-inferiority in comparison to efavirenz. The
data and safety monitoring board (DSMB) discontinued
the once daily MVC arm. This left 721 evaluable
patients in the 48 week analysis. In the primary analysis
of viral load response < 400 copies/ml, twice daily MVC
was non-inferior to efavirenz. However, in the co-pri-
mary endpoint of percentage of patients with viral load
< 50 copies/ml (65.3% MVC, 69.3% EFV), the non-
inferiority criterion was not met. There were also lower
v i r o l o g i cr e s p o n s er a t e sn o t e dw i t hM V Ci nh i g hb a s e -
line viral load patients, Southern hemisphere patients,
black patients and those with non-B subtype virus.
Upon blinded retesting of screening specimens with
the enhanced Trofile™ assay, 15% of patients had
CXCR4 tropic virus. Post hoc analysis of the study with
these CXCR4 tropic patients excluded revealed that
m a r a v i r o ct w i c ed a i l ym e tt h en o n - i n f e r i o r i t yc r i t e r i a
with efavirenz (HIV RNA < 50 copies/ml: 68.5% MVC
vs. 68.3% EFV). Additionally, response rates for mara-
viroc in the subgroup analyses improved after reanalysis,
particularly in those with high baseline viral load. Inter-
estingly, response rates for maraviroc were higher in the
Northern hemisphere, and response rates for efavirenz
were higher in the Southern hemisphere. The authors
attributed these differences to higher adverse event dis-
continuation rates for efavirenz in the Northern hemi-
sphere and higher default rates for patients receiving
maraviroc in the Southern hemisphere. The differences
noted by the DSMB for the once daily maraviroc arm
when compared to efavirenz that led to discontinuation
of that arm were no longer outside the noninferiority
thresholds in the post hoc reanalysis. In both the pri-
mary and the post hoc reanalysis, CD4 cell count
increases were 26-30 cells/mm
3 higher in the maraviroc
arm. Subsequent to the reanalysis of the MERIT data,
maraviroc was approved for use in treatment naïve
patients by the U.S. FDA.
Resistance
Although CCR5 antagonists target a host cell receptor,
virologic failure and resistance can still occur. Escape
from or resistance to CCR5 antagonists can occur
through two different mechanisms. The first is through
selection of minority variants of CXCR4 or dual/mixed
tropic virus. The second is through development of
mutations in the gp120 V3 loop, elsewhere in gp 120, or
in gp41 [81-83]. In vitro, multiple mutations in the V3
loop can lead to resistance [82,84,85]. However, no sig-
nature mutations or consistent patterns have been noted
in the same or different isolates, and the mutations
appear to be context dependent [82,84,85]. Also, devel-
opment of cross-resistance to other CCR5 antagonists
may or may not occur [81,84-86]. It is interesting to
note that in vitro primary R5 viruses in PBMCs exposed
to CCR5 antagonists usually maintain R5 tropism even
when CXCR4 receptors are abundantly available
[81,82,84,87]. It has been proposed that switching to
CXCR4 does not occur due to decreased fitness of tran-
sitional variants and/or sensitivity to CCR5 antagonists
[85,88,89].
In clinical studies, dual, mixed or CXCR4 tropic
viruses have been detected in a significant proportion of
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maraviroc. Indeed, in the MOTIVATE studies, 57% (76/
133) of MVC-treated patients with R5 tropic HIV at
baseline who experienced treatment failure had D/M or
X4 viruses detected at the time of failure. This is in con-
trast to 6/95 (6%) of those who received OBR plus pla-
cebo [77]. Similarly, in treatment naïve patients in the
MERIT study, 9/29 (31%) MVC treated patients devel-
oped X4 virus in comparison to 0/13 efavirenz treated
patients [63]. In contrast, phase 3 studies of vicriviroc in
treatment experienced patients (VICTOR E3 and 4)
detected D/M or X4 viruses in 13% (9/71) of patients
experiencing virologic failure [90]. However, it is impor-
tant to note that in the VICTOR studies, 64% of the
subjects had at least three active drugs in their regimen
which is in contrast to the maraviroc phase 3 studies in
treatment experienced patients where only 37% of
patients had at least three active drugs in their regimen.
This data is consistent with findings in the earlier phase
II vicriviroc studies in treatment experienced patients
[91,92]. The results with vicriviroc were also similar in
treatment naïve patients where 5/26 (19%) virologic fail-
ures on the vicriviroc arm developed D/M or X4 viruses
[93]. These studies also did not use the newer more sen-
sitive Trofile™ assay, and the patient population was
treatment experienced. In one report evaluating four
patients who failed vicriviroc therapy, they were found
to have the V3 loop mutations associated with failure in
minority populations (0.8-2.8%) of baseline samples [94].
Another report documented two patients who developed
X4 variants while failing treatment with maraviroc actu-
ally had those variants at baseline [95]. Thus, the emer-
g e n c eo fX 4t r o p i cv i r u si nt h e s es t u d i e sh a sb e e n
demonstrated to be most likely due to the expansion of
minority CXCR4 variants present at baseline that were
not detected with the Trofile™ assay [85,96]. Upon cessa-
tion of CCR5 antagonist therapy, those patients who
switched to dual or mixed tropism while on therapy
demonstrate reversion back to R5 tropism [95,97,98].
This suggests a fitness cost to dual or mixed tropism
in vivo which has not been observed in in vitro culture
[84,86,99]. Additionally, a post hoc analysis of the
MOTIVATE studies demonstrated a low incidence of
resistance developing to maraviroc in failing patients
who had never achieved viral suppression or had virolo-
gic rebound [100]. This data, in light of a report [101]
demonstrating that poor adherence with maraviroc was
not associated with the development of resistance, sug-
gest that maraviroc has a high barrier to resistance.
The development of mutations in the V3 loop, gp 120,
and gp 41 is the second mechanism that may present as
clinical resistance to CCR5 antagonists. These mutations
allow the resistant virus to bind to the cell’s CCR5
receptor that is already bound to maraviroc [84]. This
results in a plateau effect of the dose-response curve as
increasing drug concentration has no impact due to the
ability to utilize the maraviroc-bound receptors. In vitro,
the mutations at residues 316 and 323 have been
selected by maraviroc [84]. In vivo, mutation combina-
tions involving residues 11, 18, 10, 20, 21, 22, 25, and 26
have been linked with maraviroc treatment failure
[102,103]. In this study, it was noted that some dual tro-
p i cc l o n e sw e r er e s p o n s i v et om a r a v i r o cin vivo.O n e
patient failing treatment with vicriviroc was demon-
strated to develop V3 loop mutations which were suffi-
cient to confer resistance [97]. Interestingly, the baseline
V3 loop sequences returned once therapy with vicriviroc
was discontinued. However, others have questioned the
role of these mutations in the V3 loop in the develop-
ment of resistance to maraviroc [104]. Similarly, an eva-
luation of the viruses from 323 CCR5 antagonist naïve
patients revealed that 7.3% had mutation combinations
previously described with maraviroc resistance [105]. It
is possible that the presence of these mutations at base-
line may facilitate more rapid resistance in a patient
who does not achieve rapid viral suppression.
The implications of resistance to CCR5 antagonists
with respect to other antiretroviral agents has not been
well described; however, one report evaluated the impli-
cations in vitro a n dd e m o n s t r a t e dt h a tr e s i s t a n c et o
CCR5 inhibitors may increase the sensitivity of the resis-
tant virus to certain neutralizing antibodies [106]. This
finding will need further evaluation in vivo prior to the
consideration of developing new entry inhibitor treat-
ment sequencing strategies.
Adverse effects
The utility of an antiretroviral depends on its safety and
tolerability, as exemplified when a case of severe hepatic
cytolysis was reported in a patient being treated with
the investigational CCR5 antagonist, aplaviroc [17].
Review of aplaviroc trials revealed higher than antici-
pated elevations in ALT and total bilirubin in the apla-
viroc arms [17]. No associations were noted between
plasma drug concentrations and liver enzyme elevations.
The conclusion of the analysis was that it was an
idiosyncratic hepatotoxicity and was intrinsic to the
molecule not the class of drugs. Further aplaviroc devel-
opment was halted due to this report.
A Phase II trial of vicriviroc raised concerns for
malignancy when 6/90 subjects in the vicriviroc arms
developed malignancies compared to only 2/28 in the
placebo arm [91]. In the vicriviroc arms, there were four
lymphomas (2 Hodgkin and 2 non-Hodgkin), a gastric
adenocarcinoma, and an HPV-relate squamous cell car-
cinoma. There were no lymphomas in the placebo arm.
Concern for CCR5 antagonism leading to EBV reactiva-
tion led to evaluation of the four lymphoma patients,
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An increased rate of malignancies was not seen in the
vicriviroc arms of other studies in both treatment
experienced and treatment naïve patients including two
Phase III studies with 568 patients treated with vicri-
viroc [90,92,93].
Despite these initial safety concerns with CCR5
antagonists, maraviroc has had a remarkably clean safety
and tolerability profile. The treatment related disconti-
nuation rate due to adverse events was 3% or less in the
maraviroc arms of the trials in treatment experienced
patients [75,78]. In contrast, in treatment naïve patients,
adverse event related treatment discontinuations
occurred in 4.2% of those treated with maraviroc com-
pared with 13.6% of those treated with efavirenz [63].
Discontinuations occurred earlier with efavirenz (59% in
the first 8 weeks) compared to 40% of those treated
with maraviroc. There were no significant differences in
the incidence of serious adverse events and deaths
between the maraviroc and the placebo arms in either
the treatment experienced or the treatment naïve trials.
In the MOTIVATE trials, Category C events were not
different between arms except for esophageal candidiasis
which was more common in the maraviroc arms. Cate-
gory C events in the MERIT trial were twice as common
in the efavirenz arm compared to the maraviroc arm.
The incidence of malignancies with maraviroc was not
significantly different between arms in treatment experi-
enced patients but twice as many were seen in treat-
ment naïve patients treated with efavirenz vs. maraviroc
(Table 2).
In more than 1,300 patients treated with maraviroc in
Phase II and III studies, only one case of potentially
life-threatening hepatotoxicity has been reported, and
isoniazid and/or cotrimoxazole toxicity were actually
implicated as etiologic [63,108]. No significant differ-
ences in Grade 3/4 AST and ALT elevations between
treatment arms in either the treatment experienced or
treatment naïve patients have occurred (~3% for mara-
viroc and placebo). The effect of maraviroc on lipid pro-
file was more favorable than efavirenz in treatment
naïve patients with efavirenz having significantly greater
increases in total cholesterol (TC), LDL, and triglycer-
ides [109]. A higher proportion of patients exceeded the
National Cholesterol Education Program (NCEP)
guidelines for treatment of total cholesterol and LDL, at
both week 24 and 48, in the efavirenz group (14.4% for
TC, 6.0% LDL) compared to the maraviroc group (2.0%
TC, 1.3% LDL). When the 10 year cardiovascular risk
was calculated using the Framingham equation, the risk
was consistently higher in the efavirenz group than in
the maraviroc group. The authors concluded that
maraviroc had minimal effects of lipid profiles.
The most commonly reported side effects noted with
maraviroc in the registrational trials were headache, diz-
ziness, diarrhea, fatigue, upper respiratory tract infec-
tion, cough, abdominal pain, nasopharyngitis, rash, and
bronchitis. In the MERIT study, diarrhea, vomiting, diz-
ziness, abnormal dreams, cough and rash were more
common in the efavirenz arm while bronchitis and
nasopharyngitis were more common in the maraviroc
arm. Although postural hypotension was noted with
high doses of maraviroc early in its development, it was
not seen at significantly different rates than the com-
parator arms in the Phase II/III trials (5% MVC vs. 4%
placebo). Similarly, clinically significant QT prolongation
was not noted in the Phase IIb/III trials. As noted above
the overall rate of adverse events leading to treatment
discontinuation were low in all of these studies reinfor-
cing the favorable tolerability profile of this drug.
Trends in usage, 2010
Metabolic and cardiovascular benefits
Untreated HIV infection leads to significant cardiovas-
cular morbidity and mortality, and new data has led to
recommendations for earlier antiretroviral treatment
[110]. As HIV-infected patients live longer and take
antiretrovirals for many years, metabolic effects from
these agents are of greater concern. A number of agents
have been implicated, although the data has been con-
flicting for agents such as abacavir [111-113]. Antiretro-
viral agents with more favorable metabolic profiles are
clearly needed.
In treatment experienced patients who have a higher
rate of cardiovascular disease at baseline, the rate of car-
diovascular events seen with maraviroc treated patients
was comparable to that reported in cohort studies of
treatment experienced HIV patients, though it was
higher than in the placebo arms [96]. All of the patients
who had cardiac events in the trials had several
Table 2 Malignancies in Clinical Trials of Maraviroc
ART Experienced ART Naive
Malignancy MOTIVATE Non-R5 MVC MERIT
MVC QD MVC BID OBR MVC QD MVC BID OBR MVC EFV
Lymphoma 2 2 2 0 0 0 1 3
Kaposi Sarcoma 1 2 3 0 0 0 0 1
Other 0 0 0 1 1 1 2 3
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including diabetes, hypertension, previous myocardial
infarction, known coronary artery disease, hyperlipide-
mia, and smoking. Treatment-naïve patients treated
with maraviroc demonstrated a favorable lipid profile
and decreased cardiovascular risk when compared to
efavirenz. In the context of aging HIV-infected patients,
the relatively neutral metabolic profile of maraviroc to
date may prove useful in sparing future toxicities with
their associated morbidity and mortality.
Patients initiating antiretroviral treatment who have
pre-existing metabolic abnormalities may be candidates
for use of a CCR5 antagonist such as maraviroc. How-
ever, in patients who are virally suppressed but experi-
encing metabolic complications on their current
regimen, tropism testing cannot be done with the cur-
rently available phenotypic assay. Other genotypic assays
or assays that can be performed on stored specimens
are under study but are not currently available. This
leaves the clinician in this situation with three options:
1) avoiding the switch to maraviroc due to lack of the
tropism test, 2) testing for tropism at baseline prior to
initiation of antiretroviral therapy, or 3) using maraviroc
without tropism testing. The use of tropism testing
prior to initiation of HAART is appealing and may turn
out to have some prognostic value but is limited cur-
rently by the cost of the assay. If maraviroc is used with-
out testing, it would be reasonable to check a viral load
shortly (4-8 weeks) after switching therapy to ensure
that viral suppression is maintained.
Development of newer CCR5 antagonists may also
have a role in cardiovascular disease. One recent report
demonstrated a new CCR5 antagonist that also has
CCR2 blocking activity [22]. As CCR2 has been impli-
cated in atherosclerosis, this could prove to be beneficial
[114].
Tuberculosis
Management of the HIV-infected patient with tubercu-
losis is challenging due to drug-drug interactions
between rifampin and antiretrovirals with similar meta-
bolism through the hepatic cytochrome P450 system.
This situation is more difficult in the setting of treat-
ment experienced patients with limited treatment
options. Although maraviroc is a substrate for CYP3A4,
it can be dosed with rifampin by doubling the dose of
maraviroc to 600 mg twice daily [65].
Hepatitis B and C coinfection
Maraviroc did not appear to have a significant influence
on the incidence of hepatic adverse events in patients
coinfected with hepatitis B or C, though this assessment
was based on very small numbers of coinfected patients
[77]. Though maraviroc has proved safe to date in the
small number of coinfected patients treated, CCR5
antagonism may have potential implications for the
modulation of hepatitis B and C infections, independent
of its effect on HIV. CCR5 has been implicated in the
recruitment of T cells to the liver in chronic viral hepa-
titis leading to increases in inflammation [115]. One
study in 283 women with hepatitis C suggested less
severe hepatic inflammatory scores in individuals het-
erozygous for CCR5Δ32 [116]. However, an analysis of
14 studies could find no association between susceptibil-
ity to hepatitis C and CCR5Δ32, but the lack of consis-
tency between studies prevented an evaluation of the
impact on liver fibrosis [117]. In contrast, the absence of
CCR5 has been associated with recovery from hepatitis
B [118,119]. Administration of anti-CCR5 monoclonal
antibodies has decreased liver inflammation in a mouse
model of liver failure [120]. Although these studies sug-
gest that CCR5 antagonists could play a therapeutic role
in hepatitis B, the studies in hepatitis C have been con-
flicting and require further investigation [116,121,122].
Potential uses
Transmission
Critical to acquisition of HIV is the chemokine receptor
CCR5. The lack of surface expression of CCR5 (homo-
zygosity for CCR5Δ32) is protective against HIV acquisi-
tion, and individuals with heterozygous expression of
CCR5 have a reduced rate of disease progression
[13-15,123]. R5-tropic viruses are almost always the pre-
dominant strain in newly infected individuals in both
adults and children [124,125], and this data suggests
that drugs that block the CCR5 receptor might be parti-
cularly effective in the prevention of transmission.
Animal model studies have targeted the CCR5 recep-
tor for prevention of transmission. Analogs of RANTES,
a natural ligand of CCR5, have been evaluated as a
microbicide and prevented vaginal SHIV transmission in
Rhesus macaques [126-128]. Protection against a vaginal
SHIV challenge was also provided by vaginally delivered
fusion inhibitors and CCR5 antagonists [129,130].
Finally, oral CCR5 antagonists have protected against
vaginal SHIV challenge in macaques [131]. These
studies demonstrate the feasibility of developing microbi-
cide candidates with CCR5 antagonists, but the challenges
of developing a practical and effective formulation/delivery
system for humans remain [132]. Further investigation is
ongoing with a recent report of incorporating two antire-
troviral agents, including maraviroc, into an elastomer
vaginal ring [133].
For the reasons noted above, maraviroc seems particu-
larly well suited to be incorporated as a component of
regimens for post-exposure (occupational or non-occu-
pational) or pre-exposure prophylaxis, especially because
maraviroc attains good levels in both female and male
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Trials to evaluate maraviroc as part of PEP are planned
[135]. There has been only one reported case of mara-
viroc as part of occupational PEP, a medical student
stuck with a needle from a heavily treatment experi-
enced HIV-infected man [136]. Although it is pregnancy
category B, there is no published experience with mara-
viroc in the prevention of mother to child transmission,
but its characteristics merit consideration for preventing
vertical transmission [65].
Intensification
The maraviroc arms in the MOTIVATE trials [75], the
non-R5 tropism trial [78], and the MERIT trial [63] all
demonstrated CD4 increases significantly greater than
the comparator arms. A meta-analysis of clinical trials
using CCR5 antagonists also found a significantly
greater CD4 increase in CCR5a n t a g o n i s ta r m sc o m -
pared to regimens without one [137]. This finding led to
adding maraviroc in virally suppressed patients who
have inadequately reconstituted CD4 counts. A number
of very small studies have evaluated this question, but
none have demonstrated significant increases in CD4
counts [138-140]. Of interest, one of these studies [138]
as well as others [141,142] have reported downregula-
tion in immune activation, a finding consistent with
data from hepatitis B and C infections and graft versus
host disease. This possibility suggests potential benefit
beyond the antiviral effects of CCR5 antagonists.
Organ transplantation
Due to the role of CCR5 receptors in cell recruitment,
migration and activation and the finding of lower rejec-
tion rates in renal transplant recipients homozygous for
CCR5Δ32, there has been an interest in modulation of
CCR5 in the organ transplant setting [143]. Studies have
evaluated both acute and chronic rejection in cardiac
allograft transplantation in mice. Several studies evalu-
ated mice that received cardiac allograft transplantation
and cyclosporine and demonstrated that the mice that
were CCR5 deficient or treated with a CCR5 antibody
had prolonged allograft survival [144-146]. Prolonged
allograft survival and decreased mononuclear infiltrate
in the graft were also seen in mice treated with an anti-
CCR5 antibody and Rapamycin [147]. When the CCR5
antagonist, TAK-779, was administered to mice receiv-
ing cardiac transplants, reductions in the severity of inti-
mal lesions and the number of graft infiltrating
lymphocytes and attenuation of alloantigen-specific
T-lymphocyte proliferation and IFN-g production were
seen [148]. Another study used TAK-779 in both a mur-
ine cardiac and islet cell transplant model and found
that treatment resulted in decreased chemokine, cyto-
kine and chemokine receptor expression, prevented
recruitment of lymphocytes into the allografts, and atte-
nuated the development of chr o n i cv a s c u l o p a t h y[ 1 4 9 ] .
Similarly, in the cynomolgus monkey cardiac allograft
model, diminished activity and recruitment of CCR5-
bearing leukocytes into the graft were attenuated by use
of a CCR5 antagonist, though graft survival was only
marginally prolonged [150].
In allogeneic bone marrow transplantation, CCR5 has
been noted to be a marker for and has been implicated
in the pathogenesis of graft versus host disease (GVHD)
[151]. The absence of CCR5 has been associated with a
l o w e rr i s ko fG V H D[ 1 5 2 ] .U s eo fa na n t i - C C R 5a n t i -
body has been shown to reduce GVHD-associated liver
injury in a mouse model of GVHD [120]. These studies
s u g g e s tt h a tC C R 5a n t a g o n i s t sm a yh a v ear o l ei n
prolonging graft survival in solid organ and bone mar-
row transplantation and merit further investigation.
Other considerations
The CCR5 coreceptor modulates migration and activa-
tion of cells expressing the receptor, and so it may play
a role in infections other than HIV.
West Nile Virus (WNV)
In mice WNV infection upregulated CCR5 and its
ligand CCL5, which was associated with infiltration of
CD4 and CD8 cells into the central nervous system
(CNS); additionally, WNV infection in the absence of
CCR5 was uniformly fatal [153]. A retrospective study
in human cohorts revealed an association between
CCR5 deficiency and symptomatic WNV disease,
including death [154,155]. However, this association was
not seen with heterozygous CCR5Δ32. A more recent
study in U.S. blood donors concluded that CCR5 defi-
ciency was not by itself a risk factor for WNV acquisi-
tion but was associated with clinical symptoms of
disease [156]. The clinical implications of these findings
for patients treated with CCR5 antagonists are not yet
known. Since a CCR5 antagonist is unlikely to block all
CCR5 receptors in the body, treated patients may
respond to WNV infection in a manner similar to indi-
viduals with heterozygous CCR5Δ32. Further data from
cohort studies and clinical trials are needed before the
impact of CCR5 antagonists on WNV infection will be
fully elucidated.
Tick-borne Encephalitis (TBE)
Like WNV, TBE virus is a flavivirus that can be asso-
ciated with severe CNS disease. The findings with WNV
led to evaluations of the role of CCR5 in a small cohort
of Lithuanian patients. TBE was more frequent in
CCR5Δ32 homozygotes and the allele prevalence was
higher among TBE patients than TBE-naïve patients
with aseptic meningoencephalitis [157]. Further studies
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CCR5 antagonists are needed to confirm this association
and determine the potential impact of treatment with
CCR5 antagonists on flavivirus and other infections.
Future directions
The future roles for CCR5 antagonists in both the pre-
vention and treatment of HIV infection are likely to
expand. Recent data demonstrate the importance of
CCR5 receptor density for HIV infection [158]. The
density of CCR5 defines both the infectability of target
PBMC as well as the kinetics of HIV replication in
infected cells. Human CD8-depleted PBMC were not
able to sustain HIV infection if CCR5 receptor density
was less than 2,300 molecules per cell [158]. Physiologi-
cal levels of CCR5 range between 2,000 molecules to
10,000 molecules per cell and can vary based on the
state of immune activation.
HIV entry inhibitors’ potency is directly impacted by
the level of CCR5 expression. These include CCR5
antagonists, human antibodies that block viral entry,
and fusion inhibitors. Mild differences in CCR5 density
are associated with significant differences in IC50 and
IC90 of each inhibitor [158-160]. These observations
would suggest that as the degree of immune activation
increases with progressive HIV-induced immune dysre-
gulation, the in vivo potency of the entry inhibitor
would be altered. In addition, these data suggest that
therapy targeting immune activation may decrease
CCR5 density, and thereby enhance the antiviral potency
of entry inhibitors.
Our group has recently demonstrated that agents that
block the progression of cell cycle at the G1- S inter-
phase, are associated with downregulation of CCR5
expression. This decrease in CCR5 density is associated
with an increase in potency of both CCR5 antagonists
and HIV fusion inhibitors [160-162]. This enhancement
of antiviral activity was to the degree that CCR5-resistant
isolates demonstrated IC50’s and IC90’s of wild type iso-
lates when tested in combination with G1 cell cycle
agents, or on cells with low level of CCR5 expression
[159]. Although speculative, the clinical implication of
these findings is that the potency of CCR5 antagonists
can be significantly enhanced if used in combination with
an agent that causes down-regulation of CCR5.
Current clinical development of CCR5 agents has been
approached as if these agents were just an additional
antiviral drug to a growing number of effective anti-HIV
drugs; but in reality these drugs represent an entire new
paradigm in HIV therapeutics. Rather than acting on
HIV viral targets, CCR5 agents directly target a distinct
host cell pathway, and as such the “rules” are undoubt-
edly different than those established for agents that target
HIV viral enzymes and HIV fusion proteins. For example,
when a non-nucleoside reverse transcriptase inhibitor
binds reverse transcriptase, it inhibits that molecule
alone, yet when a CCR5 inhibitor binds CCR5 it first
alters the density available for effective viral binding. Sec-
ond it signals a down regulation of the cell’s CCR5 mole-
cules giving an effect that lasts for days. As such, there is
a significant dichotomy between drug levels and drug
effect. Another example would be the difference in resis-
tance threshold. Host targets are much less likely to alter
themselves for the benefit of the pathogen’s survival, in
distinction from the tendency of viral targets to mutate
to escape immune pressure or drug effect. These features
alone should alter what we define as the future “rules” for
the clinical use of CCR5 agents.
Over the past 25 years significant progress has been
made in HIV therapeutics. Over the next 25 years, more
advancement will certainly come. One area poised for
immediate progress is the broad application of HIV
antiretroviral therapy as the centerpiece of 21
st century
HIV prevention efforts. Fundamental to all transmissible
infectious diseases is that the infectivity of those infected
drives the epidemic. In addition, application of the
knowledge of how a pathogen completes its transmis-
sion cycle is crucial. HIV is mainly transmitted across
mucous membranes via the transmitting virus R5 tropic
stains which enter the new host via CCR5 receptors as
long as CCR5 density is adequate. As such, it is clear
that CCR5 antagonists will play a major role in the bio-
logical prevention of HIV transmission and acquisition.
It is anticipated that clinical development pathways will
carefully evaluate the role of CCR5 antagonists in the
transmission of HIV among discordant couples, both
when included as a component of the antiviral therapy
of the index case, as well as its role as a chemoprophy-
lactic drug for high risk non-HIV infected partners.
Also, of importance is the role CCR5 agents may play in
blocking re-infection among individuals who are
infected, but at risk for re-infection. The future role of
agents for targeting CCR5 is urgently waiting to be fully
defined and will require years of focused clinical investi-
gation; yet this first class targeting host cell pathways is
poised to herald a new wave in HIV therapeutic and
biological HIV prevention.
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